Article 2 Day 4_ARVO
May 8, 2025

Beyond the Genetic Code at ARVO 2025: Breakthrough Approaches to Retinal Repair

Novel therapies targeting inflammation, cell reprogramming and metabolism are showing more promise than ever. Forget one gene, one therapy—the future…

Rear,View,Of,Group,Of,Diverse,Business,People,Listening,To
May 5, 2025

Translational Research at ARVO 2025: When Clinicians and Researchers Solve Problems Together

The 2025 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Salt Lake City, Utah opened…

latest posts
Article 2 Day 4_ARVO
May 8, 2025

Beyond the Genetic Code at ARVO 2025: Breakthrough Approaches to Retinal Repair

Rear,View,Of,Group,Of,Diverse,Business,People,Listening,To
May 5, 2025

Translational Research at ARVO 2025: When Clinicians and Researchers Solve Problems Together

FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks
April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

Eylea HD for Macular Edema Following RVO
April 18, 2025

FDA Grants Priority Review to Eylea HD for Macular Edema Following RVO 

unnamed (22)
April 16, 2025

FDA Grants RMAT Designation to Atsena Therapeutics’ Gene Therapy for X-linked Retinoschisis

Thumbnail Article_Article 4 (1)
April 6, 2025

Eyeing the Future of AMD at APAO 2025

Day Round Up_Thumbnail day 2 round up
April 6, 2025

APAO-AIOC 2025: Day 2 Round-Up

Thumbnail Article_Article 3
April 5, 2025

Key Retinal Debates Sizzle in APAO-AIOC 2025 India AAO Symposium

Discover our fascinating content at issuu

explore